Tokyo, Japan

Marie Mitsui

This inventor holds 1 USPTO granted patent. Top assignee: Ribomic Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marie Mitsui. Retrieved from https://idiyas.com/inventor/marie-mitsui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marie Mitsui: Innovator in Aptamer Technology

Introduction

Marie Mitsui is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of aptamers. Her innovative work has garnered attention in the scientific community.

Latest Patents

Marie Mitsui holds a patent titled "Aptamer for IL-21 and Use Thereof." This patent represents her groundbreaking research and development in the application of aptamers for therapeutic purposes. She has successfully secured 1 patent in her field.

Career Highlights

Marie is currently employed at Ribomic Inc., a company known for its focus on RNA-based therapeutics. Her role at Ribomic Inc. allows her to further her research and contribute to advancements in medical science.

Collaborations

Marie has collaborated with her coworker, Kazuteru Aoki, to enhance the research and development of aptamer technologies. Their partnership exemplifies the collaborative spirit in scientific innovation.

Conclusion

Marie Mitsui is a trailblazer in the field of aptamer technology, with her work paving the way for future advancements in therapeutic applications. Her contributions are invaluable to the scientific community and highlight the importance of innovation in biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…